ClinicalTrials.Veeva

Menu

Markers of Atrial Fibrillation

University of California (UC) Davis logo

University of California (UC) Davis

Status

Completed

Conditions

Atrial Fibrillation
Stroke

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

This study will evaluate whether a gene marker can improve the identification of atrial fibrillation in patients with ischemic stroke, and evaluate whether the decision to anticoagulate could be improved by a marker of atrial fibrillation.

Full description

Atrial fibrillation (AF) is a major cause of ischemic stroke that is critical to identify because anticoagulation provides a 66% risk reduction in recurrent stroke. However, opportunities to prevent stroke due to AF are frequently missed because AF is paroxysmal and therefore not detected at the time of stroke. In addition, even when AF is identified anticoagulation may not be initiated due to perceived contraindications.

This study will (1) evaluate whether a gene marker can improve the identification of AF in patients with ischemic stroke, and (2) evaluate decisions by health care provider and patients to anticoagulate AF, and whether this decision could be improved by a marker of AF at time of stroke. An AF Gene Score will be developed comprised of genes associated with inflammatory and thrombotic pathways related to risk of AF thromboembolism in stroke patients with AF. The AF Gene Score measured at time of stroke can stroke will permits rapid identification of stroke due to AF which may increase initiation of anticoagulation therapy. This is important in cryptogenic stroke, where prolonged monitoring leaves uncertainty regarding the association of delayed AF with initial stroke and delays anticoagulation.

Enrollment

131 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Ischemic stroke within 72 hours of onset
  • Complete evaluation to determine cause of stroke
  • Informed Consent

Exclusion criteria

  • Active Infection
  • Lymphoma / Leukemia / Blood dyscrasia
  • Hemorrhagic stroke
  • Immunosuppressive therapy
  • Illicit drug use
  • Blood transfusion +/- 1 month
  • Major surgery/trauma in last 6mts

Trial design

131 participants in 2 patient groups

Atrial fibrillation stroke
Non-atrial fibrillation Stroke

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems